Ciclopirox nail lacquer solution 8% in the 21st century.
暂无分享,去创建一个
[1] A. Rachlis,et al. Epidemiology and prevalence of onychomycosis in HIV‐positive individuals , 2000, International journal of dermatology.
[2] M. Bohn,et al. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. , 2000, Journal of the American Academy of Dermatology.
[3] Aditya K. Gupta,et al. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. , 2000, Journal of the American Academy of Dermatology.
[4] R. Summerbell,et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter canadian survey of 15,000 patients. , 2000, Journal of the American Academy of Dermatology.
[5] N. Shear,et al. A Risk-Benefit Assessment of the Newer Oral Antifungal Agents Used to Treat Onychomycosis , 2000, Drug safety.
[6] H. Degreef,et al. Onychomycosis: predisposed populations and some predictors of suboptimal response to oral antifungal agents. , 1999, European journal of dermatology : EJD.
[7] R. Summerbell,et al. Combined distal and lateral subungual and white superficial onychomycosis in the toenails. , 1999, Journal of the American Academy of Dermatology.
[8] J. Sommadossi. HIV protease inhibitors: pharmacologic and metabolic distinctions. , 1999, AIDS.
[9] N. Shear,et al. The new oral antifungal agents for onychomycosis of the toenails , 1999, Journal of the European Academy of Dermatology and Venereology : JEADV.
[10] J. Weinberg,et al. Proximal white subungual onychomycosis in the immunocompetent patient: report of two cases and review of the literature. , 1999, Acta dermato-venereologica.
[11] S. Shuster. Hydroxy-Pyridones as Antifungal Agents with Special Emphasis on Onychomycosis , 1999, Springer Berlin Heidelberg.
[12] A. Markus. Hydroxy-Pyridones Outstanding Biological Properties , 1999 .
[13] S. Nolting. Open Studies of Ciclopirox Nail Lacquer in Onychomycosis—A Review , 1999 .
[14] B. Piraccini,et al. "Endonyx" onychomycosis: a new modality of nail invasion by dermatophytes. , 1999, Acta dermato-venereologica.
[15] C. R. Daniel,et al. Factors that may affect the response of onychomycosis to oral antifungal therapy , 1998, The Australasian journal of dermatology.
[16] R. Summerbell,et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey , 1998, The British journal of dermatology.
[17] C. R. Daniel,et al. Onychomycosis: strategies to reduce failure and recurrence. , 1998, Cutis.
[18] B. Piraccini,et al. Relapses of Onychomycosis after Successful Treatment with Systemic Antifungals: A Three-Year Follow-Up , 1998, Dermatology.
[19] B. Piraccini,et al. The prevalence of skin diseases in human immunodeficiency infection and its relationship to the degree of immunosuppression. , 1998 .
[20] P. Routledge,et al. Important Drug-Drug Interactions in the Elderly , 1998, Drugs & aging.
[21] B. Piraccini,et al. Are local and systemic conditions important for the development of onychomycosis? , 1998, European journal of dermatology : EJD.
[22] Roberts,et al. Subungual dermatophytoma complicating dermatophyte onychomycosis , 1998, The British journal of dermatology.
[23] J. Stover,et al. Projecting the impact of AIDS on mortality. , 1998, AIDS.
[24] R. Summerbell,et al. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada ‐ a multicenter survey of 2001 patients , 1997, International journal of dermatology.
[25] G. Cunningham. Adverse Drug Reactions in the Elderly and Their Prevention , 1997, Scottish medical journal.
[26] R. Baran. Proximal subungual candida onychomycosis. An unusual manifestation of chronic muco‐cutaneous candidosis , 1997, The British journal of dermatology.
[27] A. Gupta,et al. Oral antifungal drug interactions. , 1997, Dermatologic clinics.
[28] B. Piraccini,et al. Uncommon clinical patterns of Fusarium nail infection: report of three cases , 1997, The British journal of dermatology.
[29] M. Ghannoum. Future of antimycotic therapy , 1997 .
[30] B. Piraccini,et al. Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic antifungals , 1996, The British journal of dermatology.
[31] A. Tosti,et al. Autosomal dominant pattern of distal subungual onychomycosis caused by Trichophyton rubrum. , 1996, Journal of the American Academy of Dermatology.
[32] M. Baixench,et al. Onychomycose à Fusarium. , 1996 .
[33] R. Baran,et al. Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. , 1996, Acta dermato-venereologica.
[34] I. Effendy,et al. Nail incorporation kinetics of terbinafine in onychomycosis patients , 1995, Clinical and experimental dermatology.
[35] A. Polak‐Wyss. Mechanism of action of antifungals and combination therapy , 1995 .
[36] N. Shear,et al. Antifungal agents: an overview. Part II. , 1994, Journal of the American Academy of Dermatology.
[37] I. James,et al. Short‐duration therapy with terbinafine 1% cream in dermatophyte skin infections , 1994, The British journal of dermatology.
[38] N. Shear,et al. Antifungal agents : an overview. II , 1994 .
[39] M. Ciampini,et al. Recurrent tinea pedis: a double blind study on the prophylactic use of fenticonazole powder * , 1992, Mycoses (Berlin).
[40] R. Helms. Implications of Population Growth on Prevalence of Diabetes: A Look at the Future , 1992, Diabetes Care.
[41] H. Degreef,et al. Pharmacokinetic profile of orally administered itraconazole in human skin. , 1988, Journal of the American Academy of Dermatology.
[42] K. Weismann,et al. White nails in AIDS/ARC due to Trichophyton rubrum infection , 1988, Clinical and experimental dermatology.
[43] N. Noppakun,et al. Proximal White Subungual Onychomycosis in a Patient with Acquired Immune Deficiency Syndrome , 1986, International journal of dermatology.
[44] M. Magenheim. Pathways to the future. Florida's response to the geriatric imperative. , 1986, Clinics in Geriatric Medicine.
[45] R. Negroni,et al. Prophylaxis of tinea pedis interdigitalis with bifonazole, 1% powder. , 1984, Dermatologica.
[46] Mary P. Eenglish. NAILS AND FUNGI , 1976 .
[47] J. Knox,et al. Tolnaftate powder in prophylaxis of tinea pedis. , 1974, Southern medical journal (Birmingham, Ala. Print).
[48] R. Atkinson,et al. An improved method for the isolation of fungi in onychomycosis , 1973, The British journal of dermatology.